Cann Global : Export Permit Granted for Patented Canntab Hard Pill

ASX ANNOUNCEMENT

30 MARCH 2021

EXPORT PERMIT GRANTED FOR

CANNTAB'S PATENTED CANNABIS HARD PILL

Cann Global Limited (ASX:CGB) ("Cann Global" or the "Company") is pleased to announce that its joint venture partner Canntab Therapeutics Limited (CSE: PILLCN) ("Canntab") has been granted an Export Permit by Health Canada facilitating Cann Global's exclusive distribution of Canntab's hard pills in Australia.

As previously announced to the market, Cann Global has a 50/50 Joint Venture partnership with Canntab on their unique patented hard oral dose cannabinoid tablets in Australia. Canntab is a leading innovator in cannabinoid and terpene blends in hard pill form therapeutic applications. These patented hard pills are unique in their pharmaceutical grade delivery systems which also provides precise dosing. The Company is confident in the demand for these products and placed an initial order for six products from the Canntab range including two THC products, two CBD products and two THC/CBD blends.

This is the first time that Canntab has received Canadian export approval for their patented hard tablets and as Cann Global has already received an import permit, it expects to have the products available for distribution in Australia in April.

Initially the suite of products will be made available to patients through the Special Access Scheme B and Authorised prescriber schemes. Cann Global will also make the products available to the Cannabinoid Medicine Observational Study (CMOS) which recently commenced. CMOS intends to collect data from 20,000 participants nationwide and will assess the safety and efficacy of medicinal cannabis products for a range of refractory conditions including fibromyalgia, chronic pain syndromes, PTSD, epilepsy and other mental health and neurological conditions.

ABOUT CANN GLOBAL

Cann Global Limited (ASX:CGB) is a driving force in the hemp and medical Cannabis industries. Our strength comes from our team's core competencies and expertise, and our solid and strategic partnerships with experts in Australia, USA, Israel, Asia, Africa and Canada. We are working under the relevant legislation to ensure that the future in Medical Cannabis and Natural Foods will allow medical practitioners, patients, and consumers to gain access to the right information, as well as the safest, most effective and sustainable products.

AUTHORITY AND CONTACT DETAILS

This announcement has been authorised for release by Sholom Feldman, Managing Director. For further information please contact Investor Relations on [phone], or via email at [e-mail]

Cann Global Limited - ABN 18 124 873 507

Level 21, 133 Castlereagh Street, Sydney NSW 2000 - Australia

Telephone: [phone]

[e-mail]

www.cannglobal.com.au